Compare PLBL & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBL | NRIX |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2024 | 2020 |
| Metric | PLBL | NRIX |
|---|---|---|
| Price | $5.81 | $23.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 206.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $5.10 | $9.00 |
| 52 Week High | $11.75 | $28.23 |
| Indicator | PLBL | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 38.57 |
| Support Level | $5.75 | $22.56 |
| Resistance Level | $6.37 | $24.98 |
| Average True Range (ATR) | 0.40 | 0.99 |
| MACD | 0.04 | -0.28 |
| Stochastic Oscillator | 52.14 | 25.00 |
Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.